USSN: 10/809,176

Attorney Docket: 2003.002 US

Response to Office Action of March 22, 2007

Amendments to the Claims:

(Previously presented): A classic infectious bursal disease virus (IBDV) mutant that
expresses a VP2 protein that binds with monoclonal antibody (moab) B69, wherein the
VP2 protein also binds with moab 67, secreted by hybridoma cell lines HB-9437 and HB11122, deposited at the ATCC, Rockville, USA, respectively.

- (Previously presented): The classic IBDV mutant according to claim 1, wherein the VP2 protein binds with moab B69, moab 67 and moab R63, secreted by hybridoma cell line HB-9490, deposited at the ATCC, Rockville, USA.
- (Previously presented): The classic IBDV mutant according to claim 1, wherein the
 mutant comprises one or more mutations in a classic VP2 coding region, such that the
 coding region comprises,
 - (i) a codon for the amino acid at position 222 encoding an amino acid selected from the group consisting of serine and threonine, and
 - (ii) a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID. No. 1, SEQ ID. No. 2, SEQ ID. No. 3, SEQ ID. No. 4 and SEQ ID. No. 5 at positions 318-323.
- 4. (Previously presented): A classic IBDV mutant according to claim 3, wherein the coding region comprises a codon for the amino acid at position 330 encoding an amino acid selected from the group consisting of arginine and serine.

USSN: 10/809,176

Attorney Docket: 2003,002 US

Response to Office Action of March 22, 2007

5. (Previously presented): The classic IBDV mutant according to claim 1, wherein the mutant comprises one or more mutations in a VP2 coding region of IBDV strain D78.

 (Previously presented): The classic IBDV mutant according to claim 1, wherein the mutant comprises a genomic segment A of a classic IBDV, preferably of IBDV strain D78.

7. (Currently amended): A vaccine for use in the protection of An immunogenic composition for raising antibodies in poultry against disease caused by IBDV infection, wherein the vaccine comprises comprising a classic IBDV mutant according to claim 1, together with a pharmaceutical acceptable carrier or diluent.

8. (Currently amended): The vaccine immunogenic composition according to claim 7, wherein the classic IBDV mutant is in a live form.

 (Currently amended): The vaccine immunogenic composition according to claim 7, wherein the vaccine further comprises one or more vaccine components of other pathogens infectious to poultry.

10. (Currently amended): The vaccine immunogenic composition according to claim 7, wherein the vaccine comprises an adjuvant.

Claims 11-19 (Canceled).